Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26124919
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Histone acetyltransferases and histone deacetylases in B- and T-cell development,
physiology and malignancy
#MMPMID26124919
Haery L
; Thompson RC
; Gilmore TD
Genes Cancer
2015[May]; 6
(5-6
): 184-213
PMID26124919
show ga
The development of B and T cells from hematopoietic precursors and the regulation
of the functions of these immune cells are complex processes that involve highly
regulated signaling pathways and transcriptional control. The signaling pathways
and gene expression patterns that give rise to these developmental processes are
coordinated, in part, by two opposing classes of broad-based enzymatic
regulators: histone acetyltransferases (HATs) and histone deacetylases (HDACs).
HATs and HDACs can modulate gene transcription by altering histone acetylation to
modify chromatin structure, and by regulating the activity of non-histone
substrates, including an array of immune-cell transcription factors. In addition
to their role in normal B and T cells, dysregulation of HAT and HDAC activity is
associated with a variety of B- and T-cell malignancies. In this review, we
describe the roles of HATs and HDACs in normal B- and T-cell physiology, describe
mutations and dysregulation of HATs and HDACs that are implicated lymphoma and
leukemia, and discuss HAT and HDAC inhibitors that have been explored as
treatment options for leukemias and lymphomas.
free
free
free
